Roivant Sciences Future Growth
Future criteria checks 2/6
Roivant Sciences's earnings are forecast to decline at 46.3% per annum while its annual revenue is expected to grow at 60% per year. EPS is expected to decline by 50.7% per annum. Return on equity is forecast to be -13% in 3 years.
Key information
-46.3%
Earnings growth rate
-50.7%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 60.0% |
| Future return on equity | -13.0% |
| Analyst coverage | Good |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Recent updates
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Oct 22Statutory Earnings May Not Be The Best Way To Understand Roivant Sciences' (NASDAQ:ROIV) True Position
Aug 22
Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
Aug 22Roivant Sciences: Executing On Huge Buyback Program With More To Come
Jun 02Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Mar 18We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability
Feb 21These Analysts Just Made A Decent Downgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) EPS Forecasts
Nov 15Are Investors Undervaluing Roivant Sciences Ltd. (NASDAQ:ROIV) By 21%?
Apr 26Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher
Nov 22Newsflash: Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Have Been Trimming Their Revenue Forecasts
Sep 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 99 | -780 | -584 | -380 | 6 |
| 3/31/2026 | 38 | -834 | -804 | -515 | 6 |
| 3/31/2025 | 125 | -571 | -317 | -326 | 5 |
| 9/30/2024 | 129 | 4,595 | -781 | -779 | N/A |
| 6/30/2024 | 128 | 4,564 | -710 | -708 | N/A |
| 3/31/2024 | 125 | 4,349 | -767 | -765 | N/A |
| 12/31/2023 | 73 | 4,521 | -839 | -836 | N/A |
| 9/30/2023 | 53 | -927 | -851 | -848 | N/A |
| 6/30/2023 | 61 | -1,001 | -987 | -841 | N/A |
| 3/31/2023 | 61 | -1,124 | -996 | -843 | N/A |
| 12/31/2022 | 43 | -1,245 | -969 | -812 | N/A |
| 9/30/2022 | 50 | -1,178 | -1,021 | -858 | N/A |
| 6/30/2022 | 52 | -1,095 | -811 | -789 | N/A |
| 3/31/2022 | 55 | -845 | -695 | -678 | N/A |
| 12/31/2021 | 61 | -1,085 | -652 | -636 | N/A |
| 9/30/2021 | 43 | -1,061 | -614 | -605 | N/A |
| 6/30/2021 | 30 | -888 | -590 | -582 | N/A |
| 3/31/2021 | 24 | -809 | -558 | -552 | N/A |
| 12/31/2020 | 72 | -360 | -535 | -531 | N/A |
| 3/31/2020 | 68 | -456 | -764 | -759 | N/A |
| 3/31/2019 | 2 | -613 | -1,035 | -1,024 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ROIV's earnings are forecast to decline over the next 3 years (-46.3% per year).
Earnings vs Market: ROIV's earnings are forecast to decline over the next 3 years (-46.3% per year).
High Growth Earnings: ROIV's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ROIV's revenue (60% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: ROIV's revenue (60% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ROIV is forecast to be unprofitable in 3 years.